In this Breastcancer.org podcast, Suzanne Wardell, Ph.D., talks about how breast cancer drugs are developed and why some drugs never make it to market. Dr. Wardell is a research scientist at Duke University in North Carolina. Her research interests lie in understanding the processes by which breast cancers develop resistance to tamoxifen and aromatase inhibitors and in developing drugs that will target estrogen receptor activity in these resistant tumors.
Listen to the podcast to hear Dr. Wardell talk about:

bazedoxifene (BZA), a SERM approved in Europe to treat osteoporosis that has been shown to stop the growth of hormone-receptor-positive breast cancer cells

the importance of clinical trials

new research she's conducting suggesting that women diagnosed with breast cancer who do some form of moderate exercise three times a week while in treatment have better outcomes than women who don’t exercise; this applies to women who didn't exercise before being diagnosed, as well as women who did